Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female Runners

Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female Runners

The goal of this clinical trial is to describe the cardiac and systemic inflammatory adaptations specific to women practicing ultra-endurance sports.

The objectives are to:

• Improve the understanding of cardiac and systemic inflammatory adaptations specific to women participating in ultra-endurance sports.
• Assess the relationship between observed cardiac and systemic inflammatory alterations and the relative levels of estrogen, testosterone, and progesterone.
• Describe the vascular adaptations specific to women participating in ultra-endurance sports.
• Examine the influence of defense mechanisms on the emotional dynamics observed during and after an ultra-endurance race.

This is a French national non-comparative descriptive study. The study is conducted on healthy volunteers. 80 to 100 patients will be included, half of the inclusions on the "Ecotrail de Paris Ile France©"( = a trail running race in the Paris region. It is not possible to translate; it is a registered trademark) the second half of the inclusions on the "6000D©" in Savoie.

Inclusion Criteria:

• Must have a Global Positioning System watch during the race;

• Must participate in one of the following races:

  • "Ecotrail de Paris Ile France©" (=a trail running race in the Paris region, it is not possible to translate; it is a registered trademark) 80 kilometers;
  • Or "la 6000D©" 69 kilometers;

• Must comply with the race regulations:

  • Medical certificate stating no contraindications to competitive running, dated less than 12 months prior to the race;
  • Or a valid sports license on the day of the race.

• Must agree to participate in the study, sign the consent form, and allow the sponsor to use their data for the purposes of this study.

Exclusion Criteria:

• Refusal or linguistic or mental incapacity to sign the informed consent form;
• Person under guardianship (conservatorship, curators, or legal protection) or deprived of liberty;
• Person not affiliated with a social security scheme;
• Pregnant woman;
• Person participating in a drug study;
• Women with a medical history (chronic lung disease, heart disease, pharmacologically treated hypertension) or with a known significant chronic inflammatory disease at the time of the enrollment visit;
• Person who has already participated in this study in a previous race.